Thymmune Therapeutics develops cell-based immunotherapies focused on restoring immune function through thymic cell engineering. The company uses a machine learning-enabled platform to produce induced pluripotent stem cell (iPSC)-derived thymic cells that are designed for scalable, off-the-shelf manufacturing. Its research supports the development